Libor Havlı́ček

3.1k total citations · 2 hit papers
57 papers, 2.7k citations indexed

About

Libor Havlı́ček is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Libor Havlı́ček has authored 57 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Molecular Biology, 24 papers in Oncology and 15 papers in Organic Chemistry. Recurrent topics in Libor Havlı́ček's work include Cancer-related Molecular Pathways (23 papers), Cancer Mechanisms and Therapy (8 papers) and Biochemical and Molecular Research (7 papers). Libor Havlı́ček is often cited by papers focused on Cancer-related Molecular Pathways (23 papers), Cancer Mechanisms and Therapy (8 papers) and Biochemical and Molecular Research (7 papers). Libor Havlı́ček collaborates with scholars based in Czechia, France and United Kingdom. Libor Havlı́ček's co-authors include Miroslav Strnad, Sophie Leclerc, Laurent Meijer, Walter Filgueira de Azevedo, Jaroslav Veselý, Vladimı́r Kryštof, Jun‐ya Kato, J. Julian Blow, Arianna Donella‐Deana and Lénaı̈ck Détivaud and has published in prestigious journals such as PLoS ONE, Journal of Bacteriology and Chemosphere.

In The Last Decade

Libor Havlı́ček

55 papers receiving 2.6k citations

Hit Papers

Inhibition of Cyclin‐Dependent Kinases by Purine Analogues 1994 2026 2004 2015 1997 1994 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Inhibition of Cyclin‐Dependent Kinases by Purine Analogues
    1997 619 citations Sophie Leclerc, Laurent Meijer et al. European Journal of Biochemistry profile →
  2. Inhibition of Cyclin‐Dependent Kinases by Purine Analogues
    1994 562 citations Jaroslav Veselý, Libor Havlı́ček et al. European Journal of Biochemistry profile →

Peers

Libor Havlı́ček
Sophie Leclerc France
Peter L. Toogood United States
Joachim Gullbo Sweden
Stefania Sarno Italy
A. Chaikuad Germany
Jonathan M. Elkins United Kingdom
Chung-Wai Shiau Taiwan
Sanjeev Shangary United States
W. Todd Lowther United States
Akihiro Tomida Japan
Sophie Leclerc France
Libor Havlı́ček
Citations per year, relative to Libor Havlı́ček Libor Havlı́ček (= 1×) peers Sophie Leclerc

Countries citing papers authored by Libor Havlı́ček

Since Specialization
Citations

This map shows the geographic impact of Libor Havlı́ček's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Libor Havlı́ček with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Libor Havlı́ček more than expected).

Fields of papers citing papers by Libor Havlı́ček

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Libor Havlı́ček. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Libor Havlı́ček. The network helps show where Libor Havlı́ček may publish in the future.

Co-authorship network of co-authors of Libor Havlı́ček

This figure shows the co-authorship network connecting the top 25 collaborators of Libor Havlı́ček. A scholar is included among the top collaborators of Libor Havlı́ček based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Libor Havlı́ček. Libor Havlı́ček is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nisler, Jaroslav, Radka Končitíková, Jiří Voller, et al.. (2024). Cytokinin oxidase/dehydrogenase inhibitors: progress towards agricultural practice. Journal of Experimental Botany. 75(16). 4873–4890. 4 indexed citations
2.
Zeljkovıć, Sanja Ćavar, Nuria De Diego, Jaroslav Nisler, et al.. (2024). Comprehensive LC-MS/MS analysis of nitrogen-related plant metabolites. Journal of Experimental Botany. 75(17). 5390–5411. 10 indexed citations
3.
Havlı́ček, Libor, Jana Škerlová, Tomáš Pospíšil, et al.. (2023). Characterization of new highly selective pyrazolo[4,3-d]pyrimidine inhibitor of CDK7. Biomedicine & Pharmacotherapy. 161. 114492–114492. 7 indexed citations
4.
Jorda, Radek, Libor Havlı́ček, Tomáš Pospíšil, et al.. (2022). 3,5,7-Substituted Pyrazolo[4,3-d]Pyrimidine Inhibitors of Cyclin-Dependent Kinases and Cyclin K Degraders. Journal of Medicinal Chemistry. 65(13). 8881–8896. 25 indexed citations
5.
Mik, Václav, Barbora Lišková, Gabriel González, et al.. (2021). Cytoprotective activities of kinetin purine isosteres. Bioorganic & Medicinal Chemistry. 33. 115993–115993. 7 indexed citations
6.
Nisler, Jaroslav, David Kopečný, Radka Končitíková, et al.. (2020). Diphenylurea-derived cytokinin oxidase/dehydrogenase inhibitors for biotechnology and agriculture. Journal of Experimental Botany. 72(2). 355–370. 30 indexed citations
7.
Jorda, Radek, Libor Havlı́ček, Md. Mahmudul Alam, et al.. (2019). 3,5,7-Substituted Pyrazolo[4,3-d]pyrimidine Inhibitors of Cyclin-Dependent Kinases and Their Evaluation in Lymphoma Models. Journal of Medicinal Chemistry. 62(9). 4606–4623. 21 indexed citations
8.
9.
Řezníčková, Eva, Tomáš Gucký, Marek Zatloukal, et al.. (2015). 2,6,9-Trisubstituted purines as CRK3 kinase inhibitors with antileishmanial activity in vitro. Bioorganic & Medicinal Chemistry Letters. 25(11). 2298–2301. 10 indexed citations
10.
Liebl, Johanna, Vladimı́r Kryštof, Libor Havlı́ček, et al.. (2013). Trisubstituted Pyrazolopyrimidines as Novel Angiogenesis Inhibitors. PLoS ONE. 8(1). e54607–e54607. 23 indexed citations
11.
Rárová, Lucie, et al.. (2013). Amides derived from heteroaromatic amines and selected steryl hemiesters. Steroids. 78(14). 1347–1352. 11 indexed citations
12.
Jorda, Radek, Nina Sacerdoti‐Sierra, Jiří Voller, et al.. (2011). Anti-leishmanial activity of disubstituted purines and related pyrazolo[4,3-d]pyrimidines. Bioorganic & Medicinal Chemistry Letters. 21(14). 4233–4237. 34 indexed citations
13.
Zatloukal, Marek, et al.. (2008). Novel potent inhibitors of A. thaliana cytokinin oxidase/dehydrogenase. Bioorganic & Medicinal Chemistry. 16(20). 9268–9275. 66 indexed citations
14.
Kryštof, Vladimı́r, I.W. McNae, Malcolm D. Walkinshaw, et al.. (2005). Antiproliferative activity of olomoucine II, a novel 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitor. Cellular and Molecular Life Sciences. 62(15). 1763–1771. 47 indexed citations
15.
Moravec, Jiřı́, Vladimı́r Kryštof, Jan Hanuš, et al.. (2003). 2,6,8,9-Tetrasubstituted Purines as New CDK1 Inhibitors. Bioorganic & Medicinal Chemistry Letters. 13(18). 2993–2996. 23 indexed citations
16.
Kryštof, Vladimı́r, et al.. (2003). Pyrazolo[4,3-d]pyrimidines as new generation of cyclin-dependent kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 13(18). 2989–2992. 24 indexed citations
17.
Vermeulen, Katrien, Miroslav Strnad, Vladimı́r Kryštof, et al.. (2002). Antiproliferative effect of plant cytokinin analogues with an inhibitory activity on cyclin-dependent kinases. Leukemia. 16(3). 299–305. 47 indexed citations
18.
19.
Veselý, Jozef, Karel Lemr, Jan Hanuš, et al.. (1998). Metabolism of olomoucine, roscovitine, and bohemine in small laboratory rodents. Cellular & Molecular Biology Letters. 3(3). 1 indexed citations
20.
Veselý, Jaroslav, Libor Havlı́ček, Miroslav Strnad, et al.. (1994). Inhibition of Cyclin‐Dependent Kinases by Purine Analogues. European Journal of Biochemistry. 224(2). 771–786. 562 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sophie Leclerc Breakdown of academic impact, for papers by Peter L. Toogood Breakdown of academic impact, for papers by Joachim Gullbo Breakdown of academic impact, for papers by Stefania Sarno Breakdown of academic impact, for papers by A. Chaikuad Breakdown of academic impact, for papers by Jonathan M. Elkins Breakdown of academic impact, for papers by Chung-Wai Shiau Breakdown of academic impact, for papers by Sanjeev Shangary Breakdown of academic impact, for papers by W. Todd Lowther Breakdown of academic impact, for papers by Akihiro Tomida
Rankless by CCL
2026